Grant Pierson, DO
Pulmonary Disease · Joplin, MONPI 1699034900
Payments from drug & device makers
What this record shows
The money is spread across several categories — consulting fees (46.6%), speaking fees and travel and lodging — rather than concentrated in one kind of arrangement. 18 manufacturers reported payments, led by AstraZeneca at 40.7% of the total. Among pulmonary disease clinicians in MO with any reported payments, this total sits in the top 5% — high for the specialty, which is a reason to read the composition above rather than the number alone.
Across 265 payments — averaging $521.29 each. Meals, travel, consulting and speaking fees, gifts and royalties reported by drug and device makers.
- AstraZeneca$56K
- Medical Device Business Services, Inc.$30K
- Johnson & Johnson$26K
- Ethicon Endo-surgery Inc.$22K
- Olympus America Inc.$2K
- Fujifilm Healthcare Americas Corporation$546
- plus $2K from 12 others
What the payments were for
- Consulting fees$64,33847%
- Speaking & faculty fees$54,53039%
- Travel & lodging$12,3319%
- Food & beverage$6,7705%
- Education$1740%
General payments by program year
Who reported the general payments
Companies are grouped under their corporate parent — a single manufacturer often files under several CMS reporting entities. Research and ownership payments are counted separately and are not in this table.
| Company | Payments | Total |
|---|---|---|
| AstraZeneca | 82 | $56,245 |
| Medical Device Business Services, Inc. | 27 | $30,219 |
| Johnson & Johnson | 92 | $25,588 |
| Ethicon Endo-surgery Inc. | 10 | $22,458 |
| Olympus America Inc. | 5 | $1,500 |
| Fujifilm Healthcare Americas Corporation | 2 | $546 |
| Jazz Pharmaceuticals Inc. | 13 | $437 |
| GSK | 12 | $258 |
| Inspire Medical Systems, Inc. | 2 | $185 |
| Actelion Pharmaceuticals US, Inc. | 5 | $163 |
| Galvanize Therapeutics, Inc | 1 | $156 |
| Grifols USA, LLC | 6 | $113 |
| Veran Medical Technologies, Inc. | 1 | $86 |
| United Therapeutics Corporation | 1 | $73 |
| Harmony Biosciences LLC | 3 | $62 |
| Baxter Healthcare | 1 | $23 |
| Organogenesis Inc. | 1 | $19 |
| Arbor Pharmaceuticals, Inc. | 1 | $11 |
What the payments were tied to
Products named in the reported payments. Only payments of $100 or more are attributed here — the typical reported payment nationally is a meal worth about $16, and listing those product-by-product would be noise.
- Monarch Platform$66,983
- BREZTRI$55,256
- MONARCH$9,364
- Always-On Tip Tracked Forceps, 1.8mm OD, Serrated Cup$900
- SPiN Perc Localization Needle 19ga x 105mm, 1cm marking zone$900
- Spiration Valve System$600
- FUJIFILM$546
- AIRSUPRA$250
- ALIYA SYSTEM$156
- XYWAV$150
- XYREM$150
- TRELEGY ELLIPTA$120
- Inspire$102
How this compares
$138,142 in reported general payments places this provider in the 95th percentile of 295 pulmonary disease providers in Missouri.
Medicare billing
What this is not: this is the amount Original Medicare Part B allowed for services this provider billed in 2024. It is not their income. It excludes Medicare Advantage — now more than half of all Medicare enrollment — along with Medicaid and all commercial insurance, and it is gross practice revenue before staff, rent, supplies and malpractice premiums. CMS also suppresses any figure covering ten or fewer patients, so low-volume providers appear smaller than they are.
Most prescribed under Part D
| Drug | Claims | Cost to plans & patients |
|---|---|---|
| Tyvaso DpiTreprostinil | 35 | $843,796 |
| OpsumitMacitentan | 28 | $357,704 |
| Trelegy ElliptaFluticasone/Umeclidin/Vilanter | 344 | $272,025 |
| Breztri AerosphereBudesonide/Glycopyr/Formoterol | 247 | $200,553 |
| Fasenra PenBenralizumab | 15 | $83,855 |
| Spiriva RespimatTiotropium Bromide | 129 | $80,839 |
| Stiolto RespimatTiotropium Br/Olodaterol Hcl | 96 | $59,265 |
| Breo ElliptaFluticasone/Vilanterol | 102 | $50,245 |
| Anoro ElliptaUmeclidinium Brm/Vilanterol Tr | 69 | $41,233 |
| Ambrisentan | 14 | $22,273 |
| Bosentan | 14 | $17,424 |
| SymbicortBudesonide/Formoterol Fumarate | 48 | $13,679 |
| Arnuity ElliptaFluticasone Furoate | 41 | $11,801 |
| Incruse ElliptaUmeclidinium Bromide | 29 | $11,574 |
| Combivent RespimatIpratropium/Albuterol Sulfate | 19 | $10,258 |
Paid to pharmacies, not to this prescriber.
Companies that both paid and supply prescribed drugs
These companies both reported payments to this provider and make drugs the provider prescribed under Medicare Part D in 2024. For most specialties this overlap is expected — a cardiologist who is paid by a cardiology drugmaker also treats heart disease. It is shown so the reader can see it, not because it implies anything on its own.
| Company | Paid to this provider | Part D cost of their drugs |
|---|---|---|
| GSKTrelegy Ellipta, Breo Ellipta, Anoro Ellipta, Arnuity Ellipta, Incruse Ellipta | $258 | $386,878585 claims |
| Actelion Pharmaceuticals US, Inc.Opsumit, Bosentan | $163 | $375,12842 claims |
| AstraZenecaBreztri Aerosphere, Symbicort, Bevespi Aerosphere | $56,245 | $222,349310 claims |
| Johnson & JohnsonXarelto | $25,588 | $9,71717 claims |
Reading this fairly. The Part D column is what drug plans and patients paid pharmacies — this provider received none of it, and it reflects how many patients they treat and what those drugs cost. Against peers, this provider's reported payments sit in the 95th percentile of 295 pulmonary disease providers in Missouri.
Other pulmonary disease in Joplin
- Navid ZaidiJoplin$25K
- Humam FarahHannibal$840K
- Derek ByersSaint Louis$835K
- Alexander ChenSaint Louis$679K
- Joseph OjileSaint Louis$538K
- Munaf SiyamwalaIndependence$413K
- Edward CharbekSaint Louis$372K
- Adeel KhanWashington$316K
- Marin KollefSaint Louis$264K
- Praveen ChennaSaint Louis$255K
Where these figures come from
- Payments: CMS Open Payments, program years 2019–2025 (publication P06302026_06032026).
- Billing: Medicare Physician & Other Practitioners, data year 2024. Original Medicare Part B only.
- Identity: NPPES NPI Registry, July 2026.